GILEAD SCIENCES, INC. — Annual Report FY2026
Quality Scores
AI Summary
Gilead Sciences is transitioning from its legacy dominance in Hepatitis C to a diversified oncology and HIV portfolio. The 10-year data reveals a massive revenue reset followed by stabilization; revenue grew from $5.79B in 2018 to nearly $29.4B in 2025, largely due to the integration of Immunomedics and Veklury sales. However, net income exhibits extreme volatility, evidenced by a $480M low in 2024 compared to $8.5B in 2025, reflecting heavy R&D impairments and M&A costs. While the company maintains formidable cash generation, the ROI on its multi-billion dollar acquisitions remains the…
Key Changes
Gilead has undergone a massive transformation from a HCV-dominant (Hepatitis C) business to a diversified Oncology and HIV powerhouse. Following the revenue cliff from curative HCV treatments (Sovaldi/Harvoni), the company pivoted through the $11.9B Kite acquisition in 2017 to lead in CAR-T cell therapy. The 2020 pandemic introduced Veklury (remdesivir), which provided a temporary but massive cash flow tailwind that was reinvested into oncology. Today, the portfolio is shifting toward long-acting HIV treatments (Lenacapavir) and Trodelvy in oncology. This evolution reflects a movement up the value chain toward therapies with high switching costs and chronic treatment cycles. Geographic expansion has stabilized, with a focus on maximizing the commercial life-cycle of established HIV brands.
Management Commentary
Management under Daniel O'Day has pivotally shifted the company's identity from a pure-play antiviral firm to an oncology-focused biopharma. Transparancy in MD&A has improved regarding clinical trial setbacks, though the market remains skeptical of the high prices paid for growth. The execution in the HIV business remains world-class, maintaining market share despite competitive entries. Management's ability to navigate the 'patent cliff' for older drugs via new formulations like Biktarvy shows strong strategic foresight. However, the high volatility in GAAP earnings suggests a management team that is still cleaning up the balance sheet from aggressive past bidding.
Financial Highlights
Gilead's financial profile is characterized by high gross margins typical of biotech but weighed down by significant non-cash impairments. Operating income recovered strongly in 2025 reaching $10.02B after a dismal $1.66B in 2024, demonstrating the inherent lumpiness of their clinical pipeline transitions. Stockholders' equity has fluctuated between $18B and $23B over the decade, suggesting that much of the earnings are being returned to shareholders or spent on acquisitions rather than compounding internally. The debt-to-equity ratio remains elevated compared to historical levels to fund strategic pivots. Revenue growth has finally turned the corner after years of post-HCV decline, but EPS remains sensitive to pipeline setbacks.
Major Opportunities
- Consistent Cash Flow from Operations (CFO) > $8B/year
- Dominant market share in HIV therapeutics (Biktarvy)
- Strong recovery in net income for FY 2025
Major Risks
- Operating margins significantly lower than 2016 peaks
- Veklury (Covid-19) revenue is volatile and declining
- Significant patent expiration risks for HIV portfolio (2027-2033)
Unlock the full report
Full 20+ sections, charts, AI chat with the report, and PDF export are available with Premium.